Randomized Trial Of Weight Loss On Ghrelin Levels Among Breast Cancer Survivors by Puklin, Leah
Yale University 
EliScholar – A Digital Platform for Scholarly Publishing at Yale 
Public Health Theses School of Public Health 
1-1-2019 




Follow this and additional works at: https://elischolar.library.yale.edu/ysphtdl 
 Part of the Public Health Commons 
Recommended Citation 
Puklin, Leah, "Randomized Trial Of Weight Loss On Ghrelin Levels Among Breast Cancer Survivors" 
(2019). Public Health Theses. 1893. 
https://elischolar.library.yale.edu/ysphtdl/1893 
This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – 
A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an 
authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, 















RANDOMIZED TRIAL OF WEIGHT LOSS ON GHRELIN LEVELS AMONG BREAST 
CANCER SURVIVORS 





A Thesis Presented to 
The Faculty of the Yale School of Public Health 
Yale University 
 
In Candidacy for the Degree of  








Abstract .......................................................................................................................................... 3 
Methods .......................................................................................................................................... 8 
Participants and Recruitment .................................................................................................. 9 
Outcome Measures.................................................................................................................... 9 
Demographic and Medical History ..................................................................................... 9 
Body Composition Measures ............................................................................................... 9 
Ghrelin Analysis ...................................................................................................................... 10 
Weight Loss Intervention ....................................................................................................... 10 
Usual Care ............................................................................................................................... 11 
Statistical Analysis .................................................................................................................. 12 
Results .......................................................................................................................................... 13 
Study Population and Recruitment ....................................................................................... 13 
Baseline characteristics ...................................................................................................... 13 
Adherence to Intervention ..................................................................................................... 14 
Baseline Associations .............................................................................................................. 14 
Changes in Body Weight ........................................................................................................ 14 
Changes in Serum Ghrelin ..................................................................................................... 15 
Association Between Weight Loss and Ghrelin Within the Intervention Group.............. 15 
Discussion..................................................................................................................................... 16 
Acknowledgments ....................................................................................................................... 20 
References .................................................................................................................................... 21 
Appendix ...................................................................................................................................... 23 
Figure 1. Physiologic effects of ghrelin ................................................................................... 23 
Figure 2. Consort Diagram....................................................................................................... 24 
Table 1. ..................................................................................................................................... 25 
Table 2. ..................................................................................................................................... 26 
Table 3a. ................................................................................................................................... 27 
Table 3b.................................................................................................................................... 27 








Purpose: Obesity is associated with increased breast cancer risk and mortality. Ghrelin is a 
hormone that participates in a negative feedback loop to regulate body weight. Understanding the 
impact of an individualized, sustainable, dietary and exercise weight-loss intervention on 
circulating ghrelin levels could provide insight on weight control mechanisms among overweight 
and obese breast cancer survivors.  
Methods: The Lifestyle, Exercise, and Nutrition (LEAN) randomized controlled trial was a 6-
month weight loss trial conducted to examine the effect of a weight loss intervention versus 
usual care on outcomes in 151 breast cancer survivors with BMI ≥ 25 kg/m2. Fasting blood 
samples were collected at baseline and 6-months and ghrelin was measured using enzyme-linked 
immunosorbent assays (ELISA). Pearson correlation coefficients were used to examine baseline 
associations and general linear models and least square means were used to compare changes in 
ghrelin levels from baseline to 6-months between randomization groups.  
Results: Ghrelin measurements from 128 women were analyzed. At baseline, there was a 
significant positive correlation between circulating ghrelin and age (r=0.28, p<0.001) and 
significant inverse correlations with weight (r=-0.18, p=0.03), lean body mass (r=-0.18, p=0.02), 
and leptin (r=-0.18, p=0.03). After adjusting for covariates, among the intervention group, 
ghrelin levels increased by 12.08% over 6-months versus a 31.05% decrease in the usual care 
arm (p=0.04). A non-significant greater weight loss was associated with increased ghrelin 
concentrations among the intervention group (ptrend = 0.67).  
Conclusion: These findings support that greater weight loss, achieved through a sustainable diet 
and exercise intervention, is associated with increased circulating ghrelin levels in overweight or 
obese breast cancer survivors. Further research is warranted to explore whether this change 
might affect long-term maintenance of weight loss as well as to further understand the role 





In 2017, the American Cancer Society estimated there were 3,560,570 breast cancer 
survivors living in the United States with this number expected to grow to 4,571,210 breast 
cancer survivors by 2026 [1]. The increase in female breast cancer survival rates is attributable to 
widespread mammography use and improvements in treatments [1]. As the population of breast 
cancer survivors expands, it becomes increasingly important to understand the specific needs 
associated with cancer survivorship. 
Weight gain among women with breast cancer is relatively common during the first year 
of diagnosis, with weight gain commonly ranging from 2.0 to 6.0 kg [2]. Over 65% of breast 
cancer survivors are overweight or obese [3]. Factors related to post-diagnosis weight gain 
include chemotherapy, postmenopausal status, decreased physical activity and increased total 
caloric intake [4-6]. Obesity and post-treatment gain in adipose tissue places breast cancer 
survivors at an increased risk for recurrence and mortality [7]. 
Ghrelin, often referred to as the “hunger hormone”, is a 28-amino acid peptide hormone 
that plays an important role in regulating appetite [8]. Ghrelin was first isolated in 1999 in rat 
gastric mucosa [9,10]. It has since been identified that over 90 percent of ghrelin in the human 
body is found in the stomach and duodenum [11, 12]. Ghrelin is primarily produced in the gastric 
fundus by endocrine cells and stimulates pituitary Growth Hormone (GH) secretion through the 
GH secretagogue receptor [11]. Ghrelin binds to specific hypothalamic receptors to initiate 
different signaling that leads to an increase in appetite and food intake [11, 13] (Figure 1). 
Ghrelin levels fluctuate naturally throughout the day, with higher levels before food intake and 
during the night and lower levels following food consumption [14]. Studies have identified that 
plasma ghrelin levels are downregulated in patients with a BMI ≥ 30 kg/m2 compared to 
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individuals with a BMI < 25 kg/m2 with a linear inverse correlation between circulating ghrelin 
levels and body mass index [8, 14, 15]. The mechanism that explains this relationship remains 
unclear, however, it was proposed that lower plasma ghrelin concentrations observed in obesity 
represent a physiological adaptation to the positive energy balance associated with obesity [15].  
Unlike other gut-derived, meal-patterning peptides, ghrelin has been shown to play a role 
in long-term body weight regulation [9]. Administration of ghrelin to animals caused an increase 
in food intake and decreased energy expenditure, leading to weight gain, while blockage of 
ghrelin signaling led to a decrease in food intake and body weight [9, 18]. These findings suggest 
that ghrelin could participate in a negative feedback loop that regulates body weight. The 
response of circulating ghrelin to weight loss has been examined primarily in the setting of 
surgical weight loss interventions and to a lesser extent in lifestyle interventions [8, 13-17].  
Scientists have been trying to explain the success of bariatric surgery in regards to weight 
loss by evaluating changes in ghrelin concentrations that are detected following various surgical 
procedures. Currently, the published literature reporting theses effects is inconsistent. Some 
studies have indicated that only procedures isolating or removing the fundus of the stomach (e.g. 
Roux-en-Y gastric bypass (RYGBP) or Sleeve gastrectomy) show a decrease in serum ghrelin 
levels and this decrease is associated with a decrease in body mass index (BMI) [19]. It is 
hypothesized that complete removal of the gastric fundus is associated with suppression of 
ghrelin because the majority of the ghrelin-producing cells are resected [14]. For example, 
Cummings et al. studied individuals who underwent RYGBP and showed that ghrelin levels no 
longer oscillated in relation to meals and were lower than both the normal weight controls with 
an average BMI = 27.4 kg/m2 and the matched obese controls with an average BMI = 40.0 
kg/m2, regardless of the amount of weight lost [16]. This supports the notion that gastric 
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restriction which causes early satiety may suppress ghrelin and therefore may be one mechanism 
in which gastric bypass induces weight loss [19]. A recent meta-analysis of sixteen studies 
looked at the differences between short term (measuring time within or equal to 3 months) and 
long-term (measuring time exceeding 3 months) effects of RYGB surgery on ghrelin and weight 
loss [20]. This paper reported that ghrelin levels after RYGB surgery were significantly lower 
than pre-surgery levels in the short-term while ghrelin levels were markedly higher than pre-
surgery levels in the long-term [20]. Further investigation is warranted to fully understand the 
role that ghrelin plays on long-term weight loss and maintenance after bariatric surgery.  
Exploring the role circulating ghrelin levels play in lifestyle weight loss interventions is 
especially challenging given the lack of randomized controlled trials that exist today [8]. One 
prospective randomized controlled intervention trial conducted in 173 postmenopausal women 
with a BMI ≥ 25 kg/m2, found that circulating ghrelin levels significantly increased by 5.3% 
during the 12-month exercise intervention (p<0.05 compared to baseline). Individuals 
randomized to usual care (stretching) showed a non-statistically significant 2.2% increase in 
ghrelin levels over 12-months. Women randomized to the 12-month exercise intervention 
showed a 17.7% increase in ghrelin levels in response to moderate weight loss (average 3kg loss) 
without an average reduction in food intake (p<0.001 compared to baseline; p<0.01 compared 
with exercisers without weight loss at 12 months). Comparatively, women randomized to usual 
care (stretching) showed a non-statistically significant 10.7% increase in ghrelin levels over 12-
months in response to moderate weight loss (average 3kg loss) [21]. Thus, weight loss may play 
more of a role than exercise in increasing ghrelin levels. A more recent randomized controlled 
trial published by Mason et al. examined the independent and combined effects of a 12-month 
dietary weight loss and/or aerobic exercise intervention on total ghrelin levels in 398 post-
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menopausal women with a BMI ≥ 25 kg/m2 [17]. The usual care group showed a 1.8% increase 
in ghrelin over the 12-month intervention. Using the usual care group as the reference, total 
fasting ghrelin levels increased significantly in the combined diet and exercise arm (7.4%, 
p=0.008) but not in either the diet only (6.5%, p=0.07) or exercise only (1.0%, p=0.53) arms 
[17]. This study also indicated that among women randomized to the diet and exercise arm, when 
stratified by percent weight loss (≤0%, <5%, 5-10% or ≥10%) had a 3% decrease, a 3.6% 
increase, 8.4% increase and a 9.2% increase in ghrelin levels, respectively, over the 12-month 
intervention (ptrend=0.0041).  
Ghrelin has been studied in relation to many cancer types including colorectal, head and 
neck, liver, non-Hodgkin lymphoma, pancreatic, thyroid, ovarian, prostate and breast cancers 
[29]. A review written in 2017 by Au et al. summarized the current understanding of the role 
ghrelin plays in hormone dependent cancers such as breast cancer [30]. While few studies have 
examined circulating ghrelin levels in women with breast cancer or with a history of breast 
cancer, most have been focused on the effects of therapies such as chemotherapy rather than 
relating blood levels with cancer risk [30]. In the review it is suggested that while studies 
published to date have presented conflicting results regarding the effects of ghrelin on breast 
cancer with some showing pro-proliferative effects and others indicating inhibitory effects, the 
ability for ghrelin to reduce estrogen and breast cancer growth may support its use as 
therapeutics for certain cancer types in the future [30].  
Given the results of the two randomized controlled trials examining the relationship 
between lifestyle interventions and circulating ghrelin, the growing body of evidence regarding 
the association between ghrelin and hormone dependent cancers and the known risks associated 
with weight gain among breast cancer survivors, there is a need to study the link between 
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lifestyle interventions on serum ghrelin levels among this particular population. The Lifestyle, 
Exercise and Nutrition (LEAN) study examined the effects of a behavioral, dietary, and physical 
activity intervention through in-person and telephone counseling sessions, among breast cancer 
survivors. This randomized trial found an average 6.4% (in-person) and 5.4% (telephone) 
reduction in body weight for women in the lifestyle intervention arms compared to a 2.0% 
decrease in the usual care group (p<0.05 for in-person and telephone vs. controls) [3]. The 
purpose of our analysis was to examine the effect of the LEAN weight loss intervention versus 
usual care on ghrelin levels among breast cancer survivors with a body mass index (BMI) ≥ 25 
kg/m2. To our knowledge, this is the first study to examine the effects of a lifestyle weight-loss 
intervention on changes in circulating ghrelin levels among a population of breast cancer 
survivors. Understanding the impact of an individualized, sustainable dietary and exercise 
weight-loss intervention on circulating ghrelin levels could provide information on mechanisms 
associated with changes in body composition related to diet and exercise. Participants 
randomized to the weight loss intervention were hypothesized to have increased serum ghrelin 
levels after 6 months as compared to those randomized to usual care and the magnitude of 
increase would be proportional to the amount of weight lost.  
Methods 
 
The Lifestyle Exercise and Nutrition (LEAN) study was a Phase III randomized-
controlled weight loss trial evaluating the effectiveness of in-person or telephone-based weight 
loss counseling versus usual care on changes in body composition, physical activity, diet, and 
serum biomarkers over 6 months in 100 breast cancer survivors. The detailed protocol and 
primary results for the LEAN study have been published previously [3]. Based on the initial 
results, 51 additional participants were recruited and randomized to intervention or usual care to 
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increase the sample size for this study (total n=151). The Yale School of Medicine Human 
Investigation Committee approved all procedures, including written informed consent. 
 
Participants and Recruitment 
 
Eligible participants included breast cancer survivors with a BMI ≥ 25.0 kg/m2, 
diagnosed with stage 0-III breast cancer who had completed chemotherapy and/or radiation 
therapy at least 3 months before enrollment. Women had to be capable of exercising (i.e. not be 
in a wheelchair or use a cane), agree to be randomly assigned, provide informed consent to 
participate, communicate in English and be accessible by telephone. Women were excluded from 
the study if they were pregnant or intending to become pregnant in the next year, had 
experienced (past 6 months) stroke or myocardial infarction, or had severe uncontrolled mental 
illness. Breast cancer survivors were recruited between June 1, 2011 and February 1, 2016. 
Participants were identified through medical oncology clinics, self-referred via study brochures 
in the Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital and the Yale 
Cancer Center Survivorship Clinic. Details surrounding the eligibility criteria, recruitment and 




Demographic and Medical History 
 
 Medical record review and questionnaires were used to determine disease stage, surgery, 
adjuvant therapy, endocrine therapy, self-reported weight, and comorbidities at baseline and 6 
months.  




 Height and weight were measured at baseline and 6 months and rounded to the nearest 
0.1. All measurements were made by the same staff members and were performed and recorded 
twice in succession and then averaged for the analyses. Dual-energy x-ray absorptiometry scans 
were performed to assess body fat, lean body mass (LBM), and bone mineral density (BMD) at 
baseline and 6 months with a Hologic 4500 scanner. All scans were evaluated by a Radiologic 




 A fasting (≥ 12 h) blood draw was performed at baseline and 6 months. All serum 
samples were stored at -80 degree Celsius until assayed. Total ghrelin levels were measured by 
ELISA (enzyme-linked immunosorbent assays). The plasma samples from each individual were 
duplicated and analyzed using commercial ELISA kits for ghrelin (BMS2192, ThermoFisher 
Scientific, Waltham, MA). The absorbance was measured at the wavelength of 450 nm with the 
reference wavelength of 620 nm for correction using a 96-well BioTek Synergy HT microplate 
spectrophotometerreader (BioTek, Winooski, VT). All ghrelin samples were measured with 
coefficients of variation for all samples of 1.69%. Description of other serum biomarker analyses 
have been previously described [3]. Serum concentrations of insulin, leptin, and adiponectin 
were measured using radioimmunoassay kits; and C-reactive protein (CRP) was measured using 
an automated chemistry analyzer. Baseline and 6-month specimens were assayed simultaneously 
at the end of the study, and participants from the intervention and the usual care arms were 
included in each batch of assays.  Laboratory technicians were blinded to intervention 
assignment. 
 




 The lifestyle intervention for the weight loss group was designed using a combination of 
behavioral therapy, reducing caloric intake and increasing physical activity. The program was 
modified from the Diabetes Prevention Program, updated with 2010 US Dietary Guidelines and 
adapted to the breast cancer survivor population using the American Institute for Cancer 
Research/World Cancer Research Fund and American Cancer Society nutrition and physical 
activity guidelines [23, 24]. All counseling sessions provided to the participants was conducted 
by a Registered Dietitian who is a certified Specialist in Oncology Nutrition, trained in exercise 
physiology and behavior modification counseling.  
 The 6-month weight loss intervention included participants receiving individual 
counseling sessions once a week for the first month, every two weeks for months two and three, 
followed by once a month for months four, five and six. The 11 sessions, each 30 minutes in 
duration, provided individualized information on nutrition, exercise and social-cognitive theory-
based behavior strategies.  
 The dietary counseling instructed participants to reduce energy intake to a range of 1,200 
to 2,000 kcal/day based upon baseline weight and to incur an energy deficiency of 500 kcal/day. 
This reduction was promoted by maintaining a predominantly plant-based diet with education on 
portion size, tracking fat grams, reducing simple sugars, increasing fiber and incorporating 
mindful eating techniques. The physical activity program was home based, with the goal of 150 
minutes per week of moderate-intensity activity, such as brisk walking. Each participant was 
provided a pedometer and was coached to increase their daily step count to 10,000 steps per day 






 Study participants assigned to the usual care group were provided the American Institute 
for Cancer Research nutrition and physical activity brochures and were referred to the Yale 
Cancer Center Survivorship Clinic, which offers a two-session weight management program. At 
the conclusion of their 6-month participation in the usual care group, they were offered the same 
11 session in-person or telephone counseling sessions that the intervention group had received 




 Descriptive statistics were used to describe the population at baseline, stratified by 
treatment group. Baseline characteristics included age, postmenopausal status, ethnicity, level of 
education, time from diagnosis to study enrollment, body weight, BMI, disease stage, adjuvant 
treatment, and current endocrine therapy. Comparisons of baseline characteristics by 
randomization group were performed using t-tests for continuous variables and chi-square tests 
or Fischer’s exact test for categorical variables. Of the 151 LEAN participants, 149 had baseline 
serum ghrelin measurements. Those who were discontinued or lost to follow-up were dropped 
from the analysis (n=14), as well as an additional 7 participants who were missing follow-up 
blood draws, resulting in the sample size included in this analysis of 128 (84.8%) women. 
 Pearson correlation coefficients were used to examine baseline associations. General 
linear models were performed using SAS PROC GLM procedure to compare the change in 
ghrelin and weight by randomization group. Least square means and standard errors were 
calculated. Age, baseline ghrelin, and baseline BMI were included in the adjusted model, as both 
age and baseline BMI were significantly different between randomization groups at baseline. A 




Post hoc analysis examined ghrelin levels stratified by tertiles of percent of weight lost 
(≤0% weight gain or no weight loss, <4.15% weight loss, 4.15-9.5%  weight loss and >9.5% 
weight loss). Potential covariates were added to the models for exploratory analysis including 
age, baseline ghrelin, and baseline BMI.  
All analyses were performed using SAS software version 9.4 (Cary, NC). A two-sided 
type I error rate of 0.05 was used throughout the data analysis.  
Results 
 




Full recruitment details are illustrated in Fig. 2 and baseline characteristics are reported in 
Table 1. Of the 975 women assessed for eligibility, 151 women were randomized, 149 had 
baseline blood samples (Intervention=91, Usual Care=58) and 128 had 6-month blood samples 
(Intervention = 76, Usual Care = 52). Mean age of participants at baseline was 58.0 ± 7.8 years 
(mean ± SD, unless otherwise noted) and women were on average 2.9 ± 2.5 years out from 
diagnosis at the time of enrollment in LEAN. Women were predominately post-menopausal 
(83.2%), non-Hispanic white (89.1%), and highly educated, with 61% holding at least a college 
degree. Most women had been diagnosed with Stage I or II breast cancer (49.7% and 24.2% 
respectively), with 16.8% diagnosed as Stage 0 (ductal carcinoma in situ: DCIS). A majority of 
women had received adjuvant treatment from chemotherapy and/or radiation (88.6%) and 
reported some form of previous or current endocrine therapy with tamoxifen and/or aromatase 
inhibitors (64%). 
 Age, baseline body weight, baseline BMI and BMI category were found to be statistically 
significantly different between the intervention versus usual care groups, (p≤0.05). Individuals 
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randomized to the intervention were on average 59.0 ± 7.3 years old whereas those randomized 
to usual care were on average 56.3 ± 8.4 years old (p=0.04). Those randomized to intervention 
were found to have a baseline mean body weight of 85.0 ± 16.9 kg whereas baseline mean body 
weight in the usual care group was 92.3 ± 18.1 kg (p=0.01). Mean baseline BMI was 32.2 ± 6.0 
kg/m2 in the intervention group and 34.6 ± 6.7 kg/m2 in the usual care group (p=0.03). There 
were no other statistically significant differences in baseline characteristics between 
randomization groups.  
Adherence to Intervention 
 
 Over half (60.2%) of participants randomized to intervention attended all 11 weight loss 
counseling sessions, and 80.6% attended at least 80% of the counseling sessions making for high 
overall adherence across the LEAN study [3]. 
Baseline Associations 
 
 Baseline associations between circulating ghrelin and a variety of body composition and 
serum biomarkers are described in Table 2. At baseline, there was a significant positive 
correlation between circulating ghrelin level and age (r = 0.28, p<0.001). Circulating ghrelin 
levels at baseline was significantly inversely correlated with weight (r = -0.18, p=0.03), lean 
body mass (r = -0.18, p=0.02), and leptin (r = -0.18, p=0.03). Baseline ghrelin levels was not 
significantly associated with BMI, totally body fat, insulin, adiponectin or CRP.  
Changes in Body Weight 
  
 The women randomized to the intervention arm lost 5.91% of their body weight after the 
6-month intervention while those randomized to usual care lost 0.21% of their body weight. 
After adjusting for covariates, the women randomized to the intervention arm lost 5.73% of their 
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body weight after the 6-month intervention while those randomized to usual care lost 0.41% of 
their body weight. 
 
Changes in Serum Ghrelin 
 
 Mean baseline ghrelin levels by randomization group and change between baseline and 6-
months can be found in Table 3a and Table 3b. At baseline, ghrelin levels were not statistically 
significantly different between the usual care (1417.10 pg/mL ± 293.30) and intervention arms 
(1922.44 pg/mL ± 242.61) (p=0.19). After the 6-month intervention ghrelin levels differed 
significantly between study arms (Usual care=1066.99 pg/mL ± 239.20, Intervention= 2042.57 
pg/mL ± 289.17, p=0.01). After adjusting for covariates, ghrelin levels at 6-months differed 
significantly between study arms (Usual care= 1165.31 pg/mL ± 288.63, Intervention= 1975.30 
pg/mL ± 237.65, p=0.03). The change in serum ghrelin level from baseline to 6-months between 
the usual care (-493.30 pg/mL ± 258.70) and intervention arms (218.10 pg/mL ± 212.96) were 
statistically significantly different (p=0.04). Serum ghrelin levels decreased by 31.05% among 
the usual care and increased by 12.08% among the intervention group over 6-months. A 
sensitivity analysis was performed excluding those with a fasting status of less than 8 hours 
(n=7) however the results did not change significantly. 
 
Association Between Weight Loss and Ghrelin Within the Intervention Group 
  
 Table 4 presents mean change in circulating plasma ghrelin levels in the intervention 
group only, stratified by tertiles of percent weight lost (≤0% weight gain or no weight loss, 
<4.15% loss, 4.15-9.5% loss and ≥9.5% loss). Very few women in the intervention group gained 
weight or did not lose weight over 6-months (n=8). The 23 women who lost <4.15% of body 
weight showed a decrease in ghrelin levels of -310.36 pg/mL ± 461.29 (-15.85%). The 23 
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women who lost 4.15-9.5% of their body weight over the 6-month intervention showed an 
increase in ghrelin levels of 482.52 pg/mL ±  455.92 (24.54%). The 22 women who lost greater 
than or equal to 9.5% of their body weight over the 6-month intervention showed an increase in 
ghrelin levels of 494.60 pg/mL ± 480.88 (27.49%). Larger increases in ghrelin were associated 
with more weight loss in the intervention study arm (ptrend = 0.67).   
Discussion 
 
 Studies examining the role of circulating ghrelin levels on weight loss and weight 
maintenance have been primarily conducted in the setting of surgical interventions, and less so in 
the setting of lifestyle interventions [8,13-17]. A review published in 2011 on lifestyle factors 
and ghrelin implied the need for future research to focus on teasing apart the confounding effects 
of diet, weight loss and exercise [28]. Literature reviewing various bariatric surgery techniques 
have suggested that Roux-en-Y gastric bypass, a technique where the ghrelin producing cells are 
completely removed, can result in a decrease in ghrelin levels that is associated with a decrease 
in BMI [19]. It has also been proposed that since bariatric surgeries alter the gastrointestinal 
anatomy and induces early satiety, suppression of ghrelin may be one mechanism contributing to 
the success of weight loss from bariatric surgeries [16]. Comparatively, two lifestyle 
interventions, including caloric restriction and/or increased physical activity, have shown an 
inverse correlation between ghrelin levels and weight loss [17, 21]. Since obesity, weight loss 
and breast cancer are all interrelated, we sought to understand the association between weight 
loss and ghrelin levels in patients who had breast cancer. To our knowledge, this is the first study 
to examine the effect of a diet and exercise-based weight loss intervention on ghrelin levels in a 
population of breast cancer survivors.  
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The six-month LEAN intervention led to a 12.08% increase in circulating ghrelin levels 
among the intervention group. This result was consistent with the findings of two randomized 
controlled lifestyle intervention trials [17, 21]. A trial conducted by Mason et al. studied changes 
in ghrelin levels among postmenopausal women with a BMI ≥ 25kg/m2 randomized to dietary 
weight loss, moderate-to-vigorous intensity aerobic exercise, combined diet and exercise or 
control [17]. This study observed a 7.4% increase in circulating ghrelin after 12-months among 
the diet and exercise intervention arm compared to a non-significant 6.5% increase among the 
diet only arm and a 1.0% increase among the exercise only arm [17]. Similarly, a study 
performed in 2005 by Foster-Schubert et al. that randomized 173 postmenopausal women with a 
BMI ≥ 25kg/m2 to either moderate intensity aerobic exercise intervention or stretching control 
program, found similar results [21]. This study observed that women randomized to the exercise 
arm had a 5.3% increase in ghrelin levels over 12-months [21]. While we did not hypothesize a 
decrease in ghrelin levels among the usual care group in our study (-31.05%), Foster-Schubert et 
al. similarly reported a -0.6% decrease in ghrelin after 3-months followed by a 2.2% increase in 
ghrelin after 12-months in the stretching (control arms). Therefore, if our study follow-up was 
longer than 6-months we may have also seen this shift in direction. 
Similar to other studies, we found negative correlations between ghrelin and body weight 
(r=-0.18, p=0.03), BMI (r=-0.14, p=0.08), leptin (r=-0.18, p=0.03) and lean body mass (r=-0.18, 
p=0.02). These are consistent with the findings from Foster Schubert et al. who reported negative 
correlations between ghrelin and body weight (r=-.29, p<0.0001), BMI (r=-0.29, p<0.0001), lean 
body mass (r=-0.24, p=0.001) and leptin (r=-0.14, p=0.08). Tschop et al. also reported similar 
results with ghrelin levels negatively correlated with BMI (r=-0.5, p<0.01) and leptin (r=-0.39, 
p<0.05). Our results, along with previous studies, support the notion that ghrelin levels are 
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downregulated in individuals with a BMI ≥ 25kg/m2 and that the hormone leptin and ghrelin 
work inversely to regulate appetite and satiety. 
Among the diet and exercise intervention arm, Mason et al. found a -3.0% decrease in 
ghrelin levels among those who did not lose any weight, a 3.6% increase in ghrelin levels among 
those who lost less than 5% of their body weight, an 8.4% increase in ghrelin levels among 
women who lost 5-10% of their body weight and a 9.2% increase in ghrelin levels among those 
achieving a weight loss of greater than 10% [17]. Our study results were consistent with these 
findings. Individuals in the intervention arm who gained or did not lose weight showed a -
35.17% decrease in ghrelin levels, among those who lost less than 4.15% of their body weight 
showed a -15.85% decrease in ghrelin levels, among those who lost 4.15-9.5% of their body 
weight showed a 24.54% increase in ghrelin levels and among those achieving a weight loss of 
greater than 9.5%. showed a 27.49% increase in ghrelin levels. Similarly, Foster-Schubert et al. 
found that ghrelin levels increased commensurately with the amount of weight lost over the 12-
month intervention. Individuals who lost no weight (<0.5kg) showed a 0.49% increase in ghrelin, 
those who experienced mild weight loss (0.5kg-3.0kg) showed a 6.7% increase in ghrelin and 
women who lost moderate weight (>3.0kg) showed a 17.7% increase in ghrelin [21]. 
These results, taken together, indicate that ghrelin plays a role in the adaptive responses 
to weight loss. However, no study to our knowledge has prospectively examined changes in 
weight and changes in ghrelin long-term. This magnifies the need to understand the impact of 
physical activity- and diet-induced weight loss on ghrelin levels as well as the mechanisms by 
which body composition impacts ghrelin levels in the body. 
 It has been proposed that individuals with obesity and lower plasma ghrelin 
concentrations represent a physiological adaptation to the positive energy balance associated 
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with obesity [15]. Another hypothesis suggests that individuals with obesity, may have increased 
sensitivity to ghrelin and therefore require less ghrelin to stimulate hunger [26]. Individuals with 
obesity have sufficient energy stores that may suppress ghrelin secretion and therefore turn off 
the drive to eat that is usually generated by ghrelin [26]. Based on the current scientific literature, 
the mechanisms by which weight loss leads to an increase in circulating ghrelin levels is also not 
fully understood. It remains relatively unclear which aspects of body composition are related to 
the systems that regulate ghrelin in addition to how changes in these body composition 
components communicate to the ghrelin producing cells [21]. Future studies should further 
investigate which body composition factors play the biggest role in regulating ghrelin levels. 
 A potential limitation of our findings is that this intervention is limited to a 6-month 
duration, and therefore, long-term weight loss maintenance was not captured beyond 6-months.. 
Further longitudinal research and long-term follow-up assessments of weight and biomarkers is 
warranted.  
 The results of this study should also be viewed in the context that participants were 
predominately non-Hispanic white and highly educated, which may limit the generalizability of 
our findings. Also, while 151 women were enrolled in the LEAN study, 14 were discontinued or 
lost to follow-up and 7 were missing follow-up blood draws. This reduced the sample size 
available for analysis to n=128. However, only a few randomized weight loss trials in breast 
cancer survivors have been published, the majority of which have smaller sample sizes.  
Strengths of this study include a low attrition rate and high adherence to the LEAN 
intervention was high. As explained in previous LEAN results, significantly greater weight loss 
was seen in women who completed all counseling sessions compared to those who missed 
sessions [3]. Another strength of this study was the high rates of individuals who provided 
20 
 
fasting serum measurements. Overnight fasting correlates well with 24-hour profiles of ghrelin 
[27]. Of the 256 blood draws included in this analysis (128 participants with baseline and 6-
month blood draws) 249 were documented as having fasted ≥ 8 hours (97.3%). Removing 
individuals who fasted for <8 hours did not significantly alter our results. 
Multiple studies have provided evidence that maintaining a healthy weight through 
reduced caloric intake and increased physical activity can help prevent various health outcomes 
including cancer recurrence, second primary cancers and other chronic diseases [3-7]. Since 
obesity, weight loss and breast cancer are all interrelated, understanding the association between 
weight loss and ghrelin levels in women diagnosed with breast cancer becomes increasingly 
important.  
In summary, we show for the first time that ghrelin levels increased in breast cancer 
survivors undergoing a 6-month diet and physical activity, intervention. This observation is 
consistent with previous findings examining populations of postmenopausal women with obesity 
and supports the notion that future research should be performed to determine the long-term 
effect of changes in ghrelin on weight maintenance. Future studies should explore the role 
ghrelin plays, whether pro- or anti-proliferative, on hormone dependent cancers to identify how 
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Figure 2. Consort Diagram 
 
Assessed for eligibility (n=975) 
Excluded (n=824) 
   Not meeting inclusion criteria (n=459) 
   Declined to participate (n=325) 
   Unable to contact (n=40) 
Analysed (n=76) 
 
Discontinued or lost to follow-up (n=9) 
Missing follow-up blood draw (n=6) 
Allocated to intervention (n=93) 
 Complete baseline blood draw (n=91) 
Discontinued or lost to follow-up (n=5) 
Missing follow-up blood draw (n=1) 
 
Allocated to usual care (n=58) 
















Age, years, mean (SD), range (n=149) 58.0 ± 7.8 
32-73 
59.0 ± 7.3 
44-73 
56.3 ± 8.4 
32-72 
0.04 
Postmenopausal, n (%) (n=149) 124 (83.2) 77 (84.6) 47 (81.0) 0.57 
Race/Ethnicity, n (%) (n=149) 
   
0.53 
White (non-Hispanic) 131 (87.9) 82 (90.1) 49 (84.5)  
Black or African American 10 (6.7) 5 (5.5) 5 (8.6)  
Hispanic 6 (4.0) 3 (3.3) 3 (5.2)  
Other 1 (0.7) 0 (0.0) 1 (1.7)  
Declined to report 1 (0.7) 1 (1.1) 0 (0.0)  
Education, n (%) (n=149) 
   
0.17 
High school degree 19 (12.8) 10 (11.0) 9 (15.5)  
Some college degree 39 (26.2) 22 (24.2) 17 (29.3)  
College degree 38 (25.5) 29 (31.9) 9 (15.5)  
Graduate degree 53 (35.6) 30 (33.0) 23 (39.7)  
Time from diagnosis to LEAN enrollment, years, 
mean (SD) (n=147) 




Body weight, kg, mean (SD) (n=149) 87.8 ± 17.7 85.0 ± 16.9 92.3 ± 18.1 0.01 
Percent body fat (SD) (n=149) 43.2 ± 4.9 43.3 ± 4.5 42.9 ± 5.5  0.63 
Baseline BMI, kg/m2, mean (SD) (n=149) 33.2 ± 6.4 32.2 ± 6.0 34.6 ± 6.7 0.03 
BMI (kg/m2) (n=149) 
   
0.02 
Overweight BMI <30 61 (40.9) 44 (48.4) 17 (29.3)  
Obese BMI ≥ 30 88 (59.1) 47 (51.7) 41 (70.7)  
Disease stage, n (%) (n=149)    0.81 
DCIS (stage 0) 25 (16.8) 13 (14.3) 12 (20.7)  
Stage I 74 (49.7) 46 (50.6) 28 (48.3)  
Stage II 36 (24.2) 22 (24.2) 14 (24.1)  
Stage III 11 (7.4) 8 (8.8) 3 (5.2)  
Unknown 3 (2.0) 2 (2.2) 1 (1.7)  
Adjuvant treatment after surgery, n (%) (n=149)    0.38 
None 17 (11.4) 8 (8.8) 9 (15.5)  
Radiation only 57 (38.3) 34 (37.4) 23 (39.7)  
Chemotherapy only 23 (15.4) 17 (18.7) 6 (10.3)  
Radiation and chemotherapy 52 (34.9) 32 (35.2) 20 (34.5)  
Current endocrine therapy, n (%) (n=128)    0.07 
Aromatase inhibitors (AI’s) only 30 (23.4) 21 (26.3) 9 (18.8)  
Tamoxifen 43 (33.6) 20 (25.0) 23 (47.9)  
Both 9 (7.0) 6 (7.5) 3 (6.3)  











Table 2. Unadjusted baseline Pearson correlation coefficients of ghrelin levels with age, measurements of body 
composition and serum biomarkers in all study participants (n=149) 
 Correlation p-value 
Age 0.28 0.001 
Weight (kg) -0.18 0.03 
BMI (kg/m2) -0.14 0.08 
Total Body fat (kg) -0.13 0.11 
Lean Body Mass (kg) -0.18 0.02 
Leptin (ng/mL) -0.18 0.03 
Insulin (µU/mL) -0.13 0.11 
Adiponectin (µg/mg) 0.05 0.54 











Table 3a.  Unadjusted baseline, 6-month, and change in ghrelin levels by Intervention group 
(N=76) Versus Usual Care group (n=52) 
 Baseline, Mean 
(SE) 
6 Months, Mean 
(SE) 




Ghrelin (pg/mL)     
Usual Care 1417.10 (293.30) 1066.99 (239.20) -350.12 (300.25) -24.70 
Intervention 1922.44 (242.61) 2042.57 (289.17) 120.13 (248.36) 6.25 
p-value 0.19 0.01 0.23  
Weight (kg)     
Usual Care 90.34 (2.42) 90.15 (2.53) -0.19 (0.55) -0.21 
Intervention 84.80 (2.00) 79.79 (2.10) -5.01 (0.46) -5.91 
p-value 0.08 0.002 <0.001  
 
 
    
Table 3b. Adjusted baseline, 6-month, and change in ghrelin by Intervention group (N=76) 
Versus Usual Care group (n=52) 
 Baseline, Mean 
(SE) 
6 Months, Mean 
(SE) 








    
1588.98 (285.72)a 1165.31 (288.63)a -493.30 (258.70)b -31.05 
1804.84 (235.26)a 1975.30 (237.65)a 218.10 (212.96)b 12.08 
0.57 0.03 0.04  
Weight (kg)     
Usual Care 89.89 (2.43)c 89.52 (2.53)c -0.37 (0.54)c -0.41 
Intervention 85.10 (2.00)c 80.22 (2.08) c  -4.88 (0.45)c -5.73 
p-value 0.13 0.01 <0.001  
a adjusted for age, baseline BMI 
b adjusted for age, baseline BMI and baseline ghrelin 



















Table 4. 6-Month change in ghrelin levels, stratified by % weight loss among those in the intervention 
group 
                                                                     Ghrelin (pg/mL) 
    Baselinea  Changeb  
 N Mean (SE) Mean (SE) % 
Intervention     
≤0 % loss 8 2029.96 (830.35) -713.87 (792.41) -35.17 
< 4.15 % loss 23 1958.48 (483.41) -310.36 (461.29) -15.85 
4.15-9.5 % loss 23 1966.58 (477.77) 482.52 (455.92) 24.54 
≥ 9.5 % loss 22 1799.51 (503.75) 494.60 (480.88) 27.49 
Ptrend  0.99 0.67  
a adjusted for age, baseline BMI  
b adjusted for age, baseline BMI and baseline ghrelin 
